Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Medidata Solutions (MDSO)

Medidata Solutions (MDSO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Medidata Solutions 350 HUDSON ST. 9TH FLOOR NEW YORK NY 10014 USA

www.mdsol.com P: 212-918-1800

Description:

Medidata Solutions is a leading global provider of hosted clinical development solutions that enhance the efficiency of customers' clinical development processes and optimize their research and development investments. Medidata products and services allow customers to achieve clinical results more efficiently and effectively by streamlining the design, planning and management of key aspects of the clinical development process, including protocol development (Medidata Designer), investigator benchmarking and budgeting (Medidata Grants Manager), contract research organization (CRO) benchmarking and budgeting (Medidata CRO Contractor), and the capture, management, analysis and reporting of clinical trial data (Medidata Rave). Medidata's diverse customer base spans pharmaceutical, biotechnology and medical device companies, academic institutions, CROs and other research organizations, and includes some top global pharmaceutical companies.

Key Statistics

Overview:

Market Capitalization, $K 5,759,693
Shares Outstanding, K 62,456
Annual Sales, $ 635,700 K
Annual Net Income, $ 51,920 K
Last Quarter Sales, $ 180,460 K
Last Quarter Net Income, $ 7,890 K
60-Month Beta 1.22
% of Insider Shareholders 4.70%
% of Institutional Shareholders 93.30%
Float, K 59,521
% Float 95.30%

Growth:

1-Year Return 31.91%
3-Year Return 97.56%
5-Year Return 110.36%
5-Year Revenue Growth 129.62%
5-Year Earnings Growth 159.46%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.48 on 07/23/19
Next Earnings Date 10/31/19
Earnings Per Share ttm 0.87
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year -16.67%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 12/17/13

MDSO Ratios

Ratio
Price/Earnings ttm 106.02
Price/Earnings forward 118.23
Price/Earnings to Growth 6.95
Return-on-Equity % 8.64%
Return-on-Assets % 5.73%
Profit Margin % 8.17%
Debt/Equity 0.14
Price/Sales 9.06
Price/Cash Flow 54.55
Price/Book 8.72
Book Value/Share 10.58
Interest Coverage 4.16
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar